Tech Company Financing Transactions
Forlong Biotechnology Funding Round
Forlong Biotechnology, based in Suzhou, secured $17.5 million in investment from Fudan Capital, Changshu Guofa Venture and Kunsheng Relay Fund.
Transaction Overview
Company Name
Announced On
5/20/2026
Transaction Type
Venture Equity
Amount
$17,500,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to advance FL115, an IL-15 superagonist, into the pivotal clinical stage, and FL116, a PD-1/IL-18 bispecific, into clinic.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Building 1, No. 19 Yong 'an Road 310
Suzhou, 215000
China
Suzhou, 215000
China
Phone
Website
Email Address
Overview
Forlong Biotechnology is a clinical stage biotechnology company dedicated to developing next-generation cytokine therapeutics. Based on synthetic immunology, the company has established four core technology platforms, committed to overcoming the challenges of developing cytokine drugs. Focusing on tumor immunology, we develops engineering therapeutic cytokine combinations that act at distinct steps of the cancer-immunity cycle to treat cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dong Wei
Chief Financial Officer
En Ji
Chief Scientific Officer
Tianlei Ying
Chief Technical Officer
Yanling Wu
VP - R & D
Haiming Huang
Browse more venture capital transactions:
Prev: 5/20/2026: Findd venture capital transaction
Next: 5/20/2026: Variational venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. All VC database entries on this site are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs